1/11/2023- on going
PhD student in Network Oncology and Precision Medicine 39 cycle
Laboratory of Tumor Immunology and Cell Therapies (Prof. Marianna Nuti), Department of Experimental Medicine, University of Rome La Sapienza
WORKING EXPERIENCE
INTERNSHIP
Master's degree in Medical Biotechnology.
Laboratory of Tumor Immunology and Cell Therapies (Prof. Marianna Nuti), Department of Experimental Medicine, University of Rome La Sapienza
Master's degree in Medical Biotechnology.
“A.Gulino” Molecular Oncology Laboratory
Department of Molecular Medicine, University of Rome La Sapienza
Three-year degree in Biotechnology.
Laboratory of Human and Population Genomics
“Charles Darwin” Department of Biology and Biotechnology, University of Rome La Sapienza
EDUCATION AND TRAINING
2024-ongoing: 2nd Level Master in Immuno Oncology and Cell Therapies (auditor), Department of Experimental Medicine, Sapienza University of Rome, Italy.
March 2024- July 2024: Civis programme in Experimental Models in Molecular Biomedicine, Sapienza University of Rome, Italy. 1-week physical mobility at the UAM, Madrid.
May 2024: Course "Formazione generale in Salute e Sicurezza sul Lavoro (SSL) per lavoratori ed equiparati"
January 2024
Certificate of training "Preclinical Testing and Animal Welfare", Sapienza University of Rome
27/10/2023
Master's Degree in Medical Biotechnology (LM-9). University of Rome, La Sapienza
Experimental Thesis title: "CD137+ lymphocytes as biomarkers of response to anti-PD1 therapy in patients with NSCLC", at laboratory of Tumor Immunology and Cell Therapies.
March 2023- June 2023
CIVIS Program in ''Technical Innovation: Application to Immuno-Oncology'' University of Rome La Sapienza.
1 week internship at the experimental Histo-pathology laboratory (prof. Emanuelle Caraffe), CRCM, University of Marseille.
19/10/2021
Bachelor's Degree in Biotechnology (L-2). University of Rome, La Sapienza.
Experimental Thesis title: ''Evaluation of the discrimination power of rapidly mutating Y chromosome microsatellites"
2018
Secondary School Diploma
Amedeo Avogadro Scientific High School, Rome.
LABORATORY SKILLS
-Flow cytometry
-Isolation of PBMCs from blood of cancer patients by gradient centrifugation (Ficoll-Paque)
-Immunophenotyping of T cells, T Reg, exhausted T, myeloid suppressor cells (MDSC) by flow cytometry (Dx Flex, FACS Canto)
-Cell cultures (primary cultures and cell lines)
-Western Blotting
-Separation and characterization of blood components (PBMC, serum, plasma)
-Analysis of FlowJo and Prism data
-Cell lysis and protein extraction
-PCR, RT-PCR, Real-Time PCR
-RNA extraction and purification
-ELISA and Luminex assay
-MTT essay
-Senescence assay with β galactosidase
SEMINARS
-16/11/23 flowJo course: "Beyond conventional data analysis"
-13/12/23 "The MyD88-adapter-like (MAL) functions in chronic inflammatory pathways" prof. Mirza Baig
-Soft skills edition 2023
-12-15/02/24 “Single cell transcriptomics", “Spatial omics and cancer”, “Human brain organoids”, Prof. Nikolaus Rajewsky MDC Berlin
- 3/04/24 “Overcoming the obstacles faced by neoantigen cancer vaccines” Prof. Peter D. Katsikis
- 9/04/24 “Novel nanotechnologies for biomedical applications” Prof. Thanh Nguyen, UCL, London, UK
- 31/10/2024 "Spatial Transcriptomics applied to tumorigenesis and exposomes" Prof. Nikolaus Rajewsky
- 04/10/2024 "Head of EU Medical affairs dell'azienda farmaceutica Incyte", Dr. Luca Marini
- 08/10/2024 "Building a better induced regulatory T cell: Pitfalls, Progress, and Potential" Prof.ssa Lisa M. Minter
- 14/10/2024 "Towards Non-coding RNA Therapeutics" Prof. Frank Slack
- 27/11/24 Congress "Immunità e Cancro: il punto di vista dei Giovani Ricercatori"
RESEARCH ACTIVITY
Research and evaluation of prognostic and predictive biomarkers in patients affected by non-small cell lung cancer, in the absence of gene mutations, undergoing immunotherapy.
PUBLICATIONS AND ABSTRACTS
1. Gelibter A, Asquino A, Strigari L, Zizzari IG, Tuosto L, et al. CD137+ and regulatory T cells as independent prognostic factors of survival in advanced non-oncogene addicted NSCLC patients treated with immunotherapy as first-line. J Transl Med. 2024;22(1):329. doi: 10.1186/s12967-024-05142-6.
2. Gelibter A, Tuosto L (co-authors), Asquino A, Siringo M, Sabatini A., et al. Anti-PD1 therapies induce an early expansion of Ki67 + CD8 + T cells in metastatic non-oncogene addicted NSCLC patients. Front. Immunol. 2024; 15:1483182. doi: 10.3389/fimmu.2024.1483182.
3. 36th AICC international meeting-HIJACKING THE «GOOD» PATHWAYS: cancer, immunity and therapeutic approaches.
Poster: "Soluble immune biomarkers to predict clinical outcome in head and neck patients treated with immunotherapy", Asquino A, Cirillo A, Strigari L, Pace A, Napoletano C, Tuosto L, et al.
4. 36th AICC international meeting-HIJACKING THE «GOOD» PATHWAYS: cancer, immunity and therapeutic approaches.
Poster: "C-type lectins in glioblastoma: immunosuppression players and potential immune biomarkers" Pace A, Alfano C, Asquino A, Tuosto L., Valentino F, D’Angelo L, Napoletano C, Zizzari IG , Santoro A, Nuti M, Farina L, Petti M, Rughetti A.
5. SIPMeT 2024 - Translational Pathophysiology
Poster: "Novel circulating biomarkers in HNSCC patients receiving anti-PD1 therapy: the predictive and prognostic role of immunosuppressive CD137+Treg cells and LOX-1+PMN-MDSCs", Asquino A, Cirillo A, Strigari L, Pace A, Napoletano C, Tuosto L, et al.
6. 6th Intl Conf Translational Immunology SIICA, Monopoli.
Poster presentation: "Treg/CD137+ T cell balance as a novel biomarker of survival in advanced non-addicted NSCLC patients treated with immunotherapy as first-line", Tuosto L, Asquino A, Gelibter A, Strigari L, Zizzari I, et al.
7. 35th AICC international meeting, Translational and precision medicine
Poster: “Circulating CD137+ T cell subsets and MDCSs as immune biomarkers for response to anti-PD1 immunotherapy in NSCLC patients”, A. Asquino, L. Tuosto, F. Scirocchi, A. Pace, I.G. Zizzari, M. Siringo, E. Tramontano, E. Cortesi, M. Nuti, A. Rughetti, C. Napoletano.